Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels
Biochemical Journal · 2026
DOI: 10.1042/bcj20240504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2026. Verfasst von Yan Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin -Key Laborato-ry of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of …. Hauptthemen laut MEDLINE: 3-Hydroxybutyric Acid, Benzhydryl Compounds, Autophagy, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project, 天津自然科学基金会, 天津医科大学楚新一纪念医院科研资助.
Abstract (Originalsprache)
Obesity is a major contributor to chronic kidney disease, accounting for approximately 20%–25% of cases globally. In obesity-related kidney disease (OKD), ectopic lipid accumulation in renal proximal tubule cells impairs autophagic flux, exacerbating kidney injury. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, such as dapagliflozin, induce a fasting-like metabolic state and increase circulating β-hydroxybutyrate (β-HB) levels. However, the role of β-HB in modulating autophagic flux in OKD remains unclear. To investigate the potential involvement of β-HB in the renoprotective effects of dapagliflozin, diet-induced obesity (DIO) mice were used. Twelve DIO mice maintained on a high-fat diet (HFD) were randomly assigned to receive dapagliflozin or the β-HB precursor 1,3-butanediol (n = 6 per group). For each treatment, six DIO mice on HFD served as experimental models and were compared with six age-matched mice fed a standard chow diet as controls. Our study showed that dapagliflozin treatment significantly increased plasma β-HB levels and improved metabolic profiles in DIO mice. Exogenous ketone supplementation elicited similar metabolic and renoprotective effects. Both interventions enhanced autophagic flux in proximal tubule cells and attenuated structural damage in glomeruli and tubules. The renoprotective effects of dapagliflozin were associated with improved autophagic flux, suggesting that elevated β-HB levels may contribute to these benefits. The data suggest that dapagliflozin improves autophagic flux in OKD, potentially mediated by increased plasma β-HB levels. These findings provide insight into the metabolic mechanisms underlying SGLT-2 inhibitor-mediated renoprotection and highlight β-HB as a possible therapeutic target in OKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Hormones and Development, Tianjin -Key Laborato-ry of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.
- Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China.
- Jinjiang Municipal Hospital (Shanghai Sixth People's Hospital Fujian), Jinjiang 362200, China.
ORCID-Profile: Chunyan Shan
Förderung
- Tianjin Key Medical Discipline (Specialty) Construction Project
- 天津自然科学基金会
- 天津医科大学楚新一纪念医院科研资助
Zitieren
APA
Kong, Y., Peng, X., Fan, W., Zhang, L., Wu, Y., Zheng, M., & Shan, C. (2026). Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels. Biochemical Journal. https://doi.org/10.1042/bcj20240504
Vancouver
Kong Y, Peng X, Fan W, Zhang L, Wu Y, Zheng M, et al. Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels. Biochemical Journal. 2026. doi:10.1042/bcj20240504
BibTeX
@article{Kong2026,
author = {Kong, Yan and Peng, Xiaoyue and Fan, Wenying and Zhang, Li and Wu, Yijie and Zheng, Miaoyan and Shan, Chunyan},
title = {Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels},
journal = {Biochemical Journal},
year = {2026},
doi = {10.1042/bcj20240504}
}
EUVIMED